bumacor 20 mg/ml injektionsvæske, opløsning
macure pharma aps - hyoscinbutylbromid - injektionsvæske, opløsning - 20 mg/ml
fostair 100+6 mikrog./dosis inhalationsspray, opløsning
2care4 aps - beclometasondipropionat, formoterolfumarat dihydrat - inhalationsspray, opløsning - 100+6 mikrog./dosis
symbicort 4,5+160 mikrog/dosis inhalationsspray, suspension
astrazeneca a/s - budesonid, formoterolfumarat dihydrat - inhalationsspray, suspension - 4,5+160 mikrog/dosis
symbicort 4,5+160 mikrog/dosis inhalationsspray, suspension
2care4 aps - budesonid, formoterolfumarat dihydrat - inhalationsspray, suspension - 4,5+160 mikrog/dosis
symbicort turbohaler 4,5+160 mikrog/dosis inhalationspulver
paranova danmark a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
astrazeneca a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
paranova danmark a/s - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort turbuhaler 4,5+160 mikrog/dosis inhalationspulver
2care4 aps - budesonid, formoterolfumarat dihydrat - inhalationspulver - 4,5+160 mikrog/dosis
symbicort 4,5+160 mikrog/dosis inhalationsspray, suspension
paranova danmark a/s - budesonid, formoterolfumarat dihydrat - inhalationsspray, suspension - 4,5+160 mikrog/dosis
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicin for obstruktiv sygdomme, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).